Oxymorphone

Generic Name: Oxymorphone

Brand Names: Opana

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₉NO_₄

CAS Number: 76-41-5

Unique Ingredient Identifier: 9VXA968E0C

Background: An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation.

Indication: For the treatment of moderate-to-severe pain.

Associated Conditions: Anxiety, Severe Pain, Moderate Pain

Associated Therapies: Perioperative analgesia, Obstetrical analgesia therapy

Clinical Trials

Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children

Phase 3

Suspended

Conditions: Chronic Pain
Postsurgical Pain

Interventions: Drug: Oxymorphone hydrochloride (HCl)

First Posted Date: 2020-12-23

Last Posted Date: 2020-12-23

Lead Sponsor: Endo Pharmaceuticals

Target Recruit Count: 15

Registration Number: NCT04681027

Locations: 🇺🇸
Endo Clinical Trial Site #3, Orange, California, United States
🇺🇸
Endo Clinical Trial Site #5, New Orleans, Louisiana, United States
🇺🇸
Endo Clinical Trial Site #1, Oklahoma City, Oklahoma, United States

and more 2 locations

Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer

Early Phase 1

Active, not recruiting

Conditions: Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Drug: Hydrocodone
Drug: Hydromorphone
Drug: Levorphanol
Drug: Morphine
Drug: Oxycodone
Drug: Oxymorphone
Other: Questionnaire Administration

First Posted Date: 2018-07-06

Last Posted Date: 2025-03-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 43

Registration Number: NCT03579446

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

Phase 3

Terminated

Conditions: Post-Operative Pain
Acute Pain

Interventions: Drug: Oxymorphone HCl
Drug: Placebo

First Posted Date: 2016-02-22

Last Posted Date: 2021-10-26

Lead Sponsor: Endo Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT02687451

Locations: 🇺🇸
Endo Clinical Trial Site #1, Dallas, Texas, United States
🇺🇸
Endo Clinical Trial Site #4, Houston, Texas, United States
🇺🇸
Endo Clinical Trial Site #2, Durham, North Carolina, United States

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

Not Applicable

Completed

Conditions: Postoperative Nausea and Vomiting

Interventions: Procedure: Automated recommendation at the start of the case
Procedure: Automated notification at the start of surgery
Procedure: Automated notification at the end of surgery
Device: Anesthesia Information Management System (AIMS)
Device: Perioperative Data Warehouse (PDW)
Procedure: General anesthesia
Procedure: Elective surgery
Drug: Propofol
Drug: Sevoflurane
Drug: Isoflurane
Drug: Desflurane
Drug: Scopolamine
Drug: Droperidol
Drug: Haloperidol
Drug: Dexamethasone
Drug: Promethazine
Drug: Meclizine
Drug: Aprepitant
Drug: Metoclopramide
Drug: Fentanyl
Drug: Sufentanil
Drug: Alfentanil
Drug: Remifentanil
Drug: Morphine
Drug: Meperidine
Drug: Hydromorphone
Drug: Methadone
Drug: Oxycodone
Drug: Oxymorphone
Drug: Hydrocodone
Drug: Ketamine
Drug: Ondansetron
Drug: Granisetron
Drug: Dolasetron mesylate
Drug: Palonosetron
Drug: Tropisetron
Drug: Ramosetron

First Posted Date: 2015-12-09

Last Posted Date: 2019-03-07

Lead Sponsor: Vanderbilt University

Target Recruit Count: 27034

Registration Number: NCT02625181

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

Phase 3

Completed

Conditions: Post Operative Pain

Interventions: Drug: oxymorphone HCl

First Posted Date: 2010-09-28

Last Posted Date: 2021-08-20

Lead Sponsor: Endo Pharmaceuticals

Target Recruit Count: 61

Registration Number: NCT01210352

Locations: 🇺🇸
Endo Clinical Trial Site #3, Aurora, Colorado, United States
🇺🇸
Endo Clinical Trial Site #11, Oklahoma City, Oklahoma, United States
🇺🇸
Endo Clinical Trial Site #1, Little Rock, Arkansas, United States

and more 5 locations